QuidelOrtho Corporation Common Stock (QDEL) Stock
Fundamentals
Recent news

QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QDEL

Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QDEL

QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QDEL

QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QDEL
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.82 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QDEL

Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QDEL

QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QDEL

QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QDEL

QuidelOrtho Q2 Earnings Call Highlights
QuidelOrtho Q2 Earnings Call Highlights
QDEL

QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
QDEL

Implied Volatility Surging for QuidelOrtho Stock Options
Implied Volatility Surging for QuidelOrtho Stock Options
QDEL

Reasons to Add QuidelOrtho Stock in Your Portfolio for Now
Reasons to Add QuidelOrtho Stock in Your Portfolio for Now
QDEL

Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm
Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm
QDEL

4 Medical Products Stocks Poised to Win Despite Industry Headwinds
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
QDEL
About QuidelOrtho Corporation Common Stock
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian J. Blaser | President, CEO & Director | 1965 |
| Mr. Philip D. McLellan | Chief Operations Officer | 1970 |
| Mr. Jonathan P. Siegrist Ph.D. | Executive VP of Research & Development and CTO | 1982 |
| Mr. Micah Young CPA | Chief Financial Officer & Principal Financial Officer | 1979 |
| Ms. Juliet C. Cunningham | Vice President of Investor Relations | — |
| Mr. Nathaniel B. Sisitsky Esq. | Chief Legal Officer & Corporate Secretary | 1974 |
| Ms. Lisa S. Hayes | Vice President of Global Marketing & Corporate Communications | — |
| Mr. Bryan M. Hanson | Executive VP of Global Portfolio Management and Marketing | 1980 |
| Mr. Erich Wolff | Executive Vice President of Strategy & Corporate Development | — |
| Mr. Ronald Lee Bowman | Chief Human Resources Officer | 1979 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
2 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.8 | -1.2 | +7.3 | -6.7 | ||||||||
| 2022 | -23.0 | +3.4 | +8.6 | -11.7 | -6.1 | +4.8 | +5.1 | -22.2 | -10.3 | +23.3 | -4.3 | -8.5 |
| 2023 | +0.7 | -1.8 | +4.2 | +0.3 | -7.4 | -3.3 | +4.9 | -3.2 | -12.7 | -16.0 | +13.6 | +6.5 |
| 2024 | -8.3 | -34.3 | +5.3 | -13.7 | +11.4 | -26.1 | +24.2 | +0.6 | +11.2 | -13.9 | +4.9 | +8.8 |
| 2025 | -3.5 | -6.0 | -10.4 | -18.5 | +10.0 | -2.8 | -22.7 | +25.8 | +4.2 | -13.6 | -1.3 | +7.9 |
| 2026 | -5.6 | -17.8 | -27.3 | -25.8 | +3.0 | +32.0 | -7.8 | -18.5 | -20.4 |



